Table 3.
IC50 of EtGIPL1a against human cancer cell lines. MTT assays were performed 48 h after treatment with EtGIPL1a. The IC50 the data shown is an average taken from two independent experiments.
| Cell lines | Types | IC50 (nM) |
|---|---|---|
| DU145 | Human prostate cancer | 50.6 |
| HCT116 | Human colon cancer | 122.2 |
| U87 | Human glioblastoma | 136 |
| SVG | Immortalized human fetal glial cells | 144.6 |
| U251 | Human glioblastoma | 193.2 |
| HeLa | Human cervical cancer | 287.9 |
| Panc-1 | Human pancreatic cancer | 343.2 |
| MD-MB-231 | Human breast cancer | 514.3 |
| SKOV-3 | Human ovarian cancer | 634.2 |
| MCF-7 | Human breast cancer | 839.5 |
| SW480 | Human colon cancer | 1446 |